Jiangsu Nhwa Pharmaceutical (002262.SZ) has received a notification of approval for clinical trial of a Class 1 chemical drug.

Jiangsu Nhwa Pharmaceutical (002262.SZ) announced that the company recently received approval from the National Medical Products Administration (NMPA) for the clinical trial of Class 1 chemical drug NH160030 in four specifications. The company will soon commence the clinical trial. According to the Drug Administration Law of the People's Republic of China and relevant regulations, after review, NH160030, which was accepted on September 3, 2024, meets the requirements for drug registration. The drug is approved for clinical trials for cancer pain. NH160030 is an orally active selective -opioid receptor agonist, representing a new generation of opioid analgesics. Preclinical trial results have shown that compared to commonly used opioid analgesics such as morphine and hydrocodone, it has better efficacy and fewer side effects.